Last reviewed · How we verify
PD-1 / PD-L1 monoclonal antibody
This monoclonal antibody blocks the PD-1/PD-L1 immune checkpoint pathway to restore anti-tumor T cell activity.
This monoclonal antibody blocks the PD-1/PD-L1 immune checkpoint pathway to restore anti-tumor T cell activity. Used for Various solid tumors and hematologic malignancies (specific approved indications not definitively established from provided information).
At a glance
| Generic name | PD-1 / PD-L1 monoclonal antibody |
|---|---|
| Also known as | Radiotherapy. |
| Sponsor | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
| Drug class | PD-1/PD-L1 inhibitor |
| Target | PD-1 and/or PD-L1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
PD-1 and PD-L1 are inhibitory signals that cancer cells use to suppress immune responses. By blocking this interaction with a monoclonal antibody, the drug releases the brakes on T cells, allowing them to recognize and attack cancer cells more effectively. This mechanism restores the body's natural anti-tumor immunity.
Approved indications
- Advanced or metastatic cancers (specific indications not clearly specified in available data)
Common side effects
- Fatigue
- Immune-related pneumonitis
- Immune-related hepatitis
- Immune-related colitis
- Rash
- Hypothyroidism
Key clinical trials
- HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer (NA)
- Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial (PHASE2)
- Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (PHASE2)
- Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma (PHASE2)
- Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma (PHASE2)
- Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy (PHASE1)
- Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer. (PHASE2)
- Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: